Poolbeg Pharma (LON:POLB) Stock Price Up 2.9% – What’s Next?

Shares of Poolbeg Pharma PLC (LON:POLB) shot up 2.9% during mid-day trading on Wednesday . The company traded as high as GBX 7.18 and last traded at GBX 7.10. 301,551 shares traded hands during trading, a decline of 81% from the average session volume of 1,622,017 shares. The stock had previously closed at GBX 6.90.

Wall Street Analyst Weigh In

Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a research note on Tuesday, June 16th.

Poolbeg Pharma Stock Performance

The stock’s 50 day moving average price is GBX 6.24 and its 200 day moving average price is GBX 5.03. The firm has a market cap of £50.06 million, a PE ratio of -7.55 and a beta of 1.82.

Poolbeg Pharma (LON:POLB) last announced its quarterly earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. Analysts forecast that Poolbeg Pharma PLC will post -0.68 earnings per share for the current year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.